Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study

• Published in: Cancers 2024-04, Vol.16 (7), p.1378
• Main Authors: Sewastjanow-Silva, Matheus, Xiao, Lianchun, Gonzalez, Graciela N, Wang, Xuemei, Hofstetter, Wayne, Swisher, Stephen, Mehran, Reza, Sepesi, Boris, Bhutani, Manoop S, Weston, Brian, Coronel, Emmanuel, Waters, Rebecca E, Rogers, Jane E, Smith, Jackie, Lyons, Larry, Reilly, Norelle, Yao, James C, Ajani, Jaffer A, Murphy, Mariela Blum
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Adenocarcinoma; Adjuvant treatment; Adverse events; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Disease; Diseases; Esophageal cancer; Esophagus; Fluorouracil; Hepatitis; Immunotherapy; Lung cancer; Lymphatic system; Metastases; Metastasis; Monoclonal antibodies; Oxaliplatin; Patients; PD-1 protein; Radiation therapy; Relapse; Safety; Standard of care; Surgery; Survival; Toxicity; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16071378

Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve surgical resection, and prolong event-free and overall survival (OS). Building on the recent evidence that PD-1 inhibition plus chemotherapy improves the OS of patients with metastatic GEJ adenocarcinoma, we evaluated whether the application of this strategy in the neoadjuvant setting would improve the pathological response. This single-center phase I/II trial evaluated the safety, toxicity, and efficacy of neoadjuvant atezolizumab with oxaliplatin and 5-fluorouracil (modified FOLFOX) followed by esophagectomy followed by atezolizumab. The primary objective goal was to achieve 20% pathCR. From the twenty enrolled patients, eighteen underwent resection and two (10%, 95% CI: 1.24-31.7%) achieved pathCR. After a median follow-up duration of 40.7 months, 11 patients had disease recurrence and 10 had died. The median disease-free and OS were 28.8 (95% CI: 14.7, NA) and 38.6 months (95% CI: 30.5, NA), respectively. No treatment-related adverse events led to death. Although modified FOLFOX plus atezolizumab did not achieve the expected pathCR, an acceptable safety profile was observed. Our results support the continued development of a more refined strategy (neoadjuvant chemotherapy plus perioperative immunotherapy/targeted agents) with molecular/immune profiling in parallel.